Annexon Inc.

News & Events

Press Releases

In The Media

1. Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

   GlobeNewswire MAY 29, 2025 4:05 PM EDT
   BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceuti...
   READ ARTICLE

2. Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

   GlobeNewswire MAY 19, 2025 4:05 PM EDT
   First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guil...
   READ ARTICLE

3. Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire MAY 16, 2025 4:05 PM EDT
   BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceuti...
   READ ARTICLE

4. Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

   GlobeNewswire MAY 12, 2025 8:00 AM EDT
   FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Sch...
   READ ARTICLE

5. Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

   GlobeNewswire MAY 9, 2025 5:00 PM EDT
   First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) o...
   READ ARTICLE

6. Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

   GlobeNewswire MAY 7, 2025 8:00 AM EDT
   Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who h...
   READ ARTICLE

7. Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire APR 16, 2025 4:05 PM EDT
   BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceu...
   READ ARTICLE

8. Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

   GlobeNewswire APR 8, 2025 4:05 PM EDT
   Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubar...
   READ ARTICLE

9. Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

   GlobeNewswire APR 3, 2025 6:18 PM EDT
   Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potenti...
   READ ARTICLE

10. Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire MAR 17, 2025 4:05 PM EDT
    BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceu...
    READ ARTICLE